We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Enzyme hyaluronidase shows promise as treatment for muscle stiffness caused by brain injury
News

Enzyme hyaluronidase shows promise as treatment for muscle stiffness caused by brain injury

Enzyme hyaluronidase shows promise as treatment for muscle stiffness caused by brain injury
News

Enzyme hyaluronidase shows promise as treatment for muscle stiffness caused by brain injury

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Enzyme hyaluronidase shows promise as treatment for muscle stiffness caused by brain injury"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A naturally occurring enzyme called hyaluronidase may be an effective alternative treatment for spasticity, or muscle stiffness, a disabling condition in people who have had a stroke or other brain injury.


That is the finding of a study from New York University (NYU) Langone Medical Center published in EBioMedicine, along with a corresponding commentary.


The study found that injections of hyaluronidase reduced muscle stiffness in patients with neurological injury without causing muscle weakness like conventional treatments such as botulinum toxin.


See Also: Spinal stimulation helps four patients with paraplegia regain voluntary movement


"These findings fill a critical gap in the understanding of muscle stiffness, and present a promising treatment for spasticity, a vexing problem that affects millions of people worldwide," says lead study author Preeti Raghavan, MD, assistant professor in the Department of Rehabilitation Medicine and director of Motor Recovery Research at Rusk Rehabilitation at NYU Langone.


Spasticity refers to hyperactive reflexes after neurological injury, but a major problem occurs when the spastic muscles become stiff or rigid and impede joint movement, causing pain, muscle contracture, and disability. Along with stroke, common causes of spasticity include traumatic brain injury, spinal cord injury, cerebral palsy, brain tumors, and multiple sclerosis.


Although a well-established symptom of neurological injury, the factors that worsen spasticity remain poorly understood. Current treatments include central nervous system depressants taken orally, and injectable medications like botulinum toxin, but both cause muscle weakness, which can further impede movement without addressing the stiffness patients feel.


Raghavan and colleagues developed an alternative theory for the cause of muscle stiffness following a central nervous system injury they call the "Hyaluronan Hypothesis." It postulates that the accumulation of hyaluronan—a sugar molecule and common lubricant in joints and muscles—promotes the development of muscle stiffness. When a brain injury limits a person's mobility, hyaluronan thickens like honey, which can lead to abnormal sliding of muscle fibers and result in stiffness. Therefore, the researchers believed that an enzyme that breaks down such molecular sugar chains, called hyaluronidase, may reduce their concentration in muscles to reduce stiffness and increase joint movement.


Learn More: Case study: Repeated stimulation treatment restores movement to paralyzed muscles


To test this theory, researchers enrolled 20 patients between 10 and 77 years of age, who experienced moderate to severe upper limb stiffness in more than one joint following a neurological injury and had exhausted all available conventional treatments with limited benefits. Each received injections of hyaluronidase at NYU Langone's outpatient hand clinic located at the Hospital for Joint Diseases.


Patients underwent video-recorded neurological and musculoskeletal assessments to document their movement restriction and muscle stiffness at four points: prior to injection, 2 weeks post-injection, 4 to 6 weeks after injection, and within 3 to 5 months of injection. Unbiased nurses not involved in the study documented any complaints in medical records.


Prior to the injections, 50.6 percent of the joints tested showed moderate stiffness and 44.4 percent of the joints tested showed severe stiffness, as captured by the Modified Ashworth Scale, a standard measure of stiffness. This number dropped to 15.3 percent with moderate stiffness and 5.8 percent with severe stiffness within 2 weeks of the injections.


Hyaluronidase took effect within days to two weeks, with effects that lasted for at least three months. The treatment did not produce muscle weakness or clinically significant side effects in the reported case series.


Hyaluronidase may provide a relatively less expensive option for patients with spasticity, according to Raghavan. One vial of hyaluronidase typically costs $50, and a single treatment may require 4 to 8 vials, while one vial of botulinum toxin may cost at least $500, and treatment may require up to 4 or more vials.


Raghavan plans to begin a clinical trial to further study the effects of hyaluronidase in a greater number of patients, and adds that more research is needed to determine the effects of repeated hyaluronidase administrations overtime, although 15 of the 20 patients returned for additional injections.


Read Next: Researchers more accurately define role of dopamine neurons in movement


"This case series provides preliminary evidence for the safety and potential efficacy of hyaluronidase injections as a treatment for muscle stiffness that may enhance recovery in the spastic upper limb. More research may determine whether such a treatment is applicable to other disorders characterized by muscle stiffness," says Raghavan. Hyaluronidase treatment for muscle spasticity is considered off-label. No pharmaceutical funding was received, and NYU Langone has filed a patent for hyaluronidase for muscle stiffness.


Note: Material may have been edited for length and content. For further information, please contact the cited source.


NYU Langone Medical Center


Publication

Raghavan P et al. Human Recombinant Hyaluronidase Injections For Upper Limb Muscle Stiffness in Individuals With Cerebral Injury: A Case Series.   EBioMedicine, Published July 2016. doi: 10.1016/j.ebiom.2016.05.014


Advertisement